2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2666

Therapeutic Efficacy of Iguratimod in Patients with Primary Sjogren’s Syndrome
Abstract Number: 2889

Therapeutic Plasma Exchange for the Treatment of Raynaud’s and Digital Ulcers in Systemic Sclerosis: A Systematic Review
Abstract Number: 1448

Therapeutic Role of a Novel Histone Deacetylase 6 Inhibitor, CKD-M808, in Rheumatoid Arthritis
Abstract Number: 1905

Therapeutic Targeting of JAK/STAT Pathway Inhibits Follicular Helper T Cell Maturation and Function
Abstract Number: 617

Therapy in Patients with Rheumatoid Arthritis (RA) with Inadequate Response to Tumor Necrosis Factor Alpha Inhibitors (TNFi): A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs
Abstract Number: 2605

Therapy with Biologic Agents after Diagnosis of Solid Malignancies; Results from the Corrona Registry
Abstract Number: 560

There Is No Further Gain from Calculating Disease Activity Score in 28 Joints with High Sensitivity Assays of C-Reactive Protein Because of High Intraindividual Variability of CRP: A Cross Sectional Study and Theoretical Consideration
Abstract Number: 2308

Thigh Muscle MRI Reveals Extensive Muscle Edema and Early Fatty Replacement in Patients with Immune-Mediated Necrotizing Myopathy
Abstract Number: 1175

Thirty Day Readmission Rates for Patients Diagnosed with Systemic Lupus Erythematosus: Analysis at a Tertiary Care Center
Abstract Number: 2080

Three Simple Tests to Raise the Index of Suspicion for Fibromyalgia in Primary Care
Abstract Number: 2505

Thresholds of Benefit-Risk Trade-Offs from the Patient Perspective for Treatment Decisions in Moderate-to-Severe Rheumatoid Arthritis
Abstract Number: 2964

Thromboangiitis Obliterans (Buerger’s disease) : An Observational Study of 174 Patients
Abstract Number: 1963

Thrombospondin-1 Is Elevated in the Plasma of Patients with Antiphospholipid Syndrome and Is Correlated with Free Active TGF-b1 Levels, IL-1b and IL-17A
Abstract Number: 653

Thrombospondin-1 Is Highly Expressed By Salivary Gland Epithelial Cells of Sjögren’s Syndrome Patients, Both Constitutively and upon Exposure to Necrotic Cells Debris
Abstract Number: 2597

Time to Initiation of Biologic Agents Is Associated with Glucocorticoid Use: Results from the Corrona Registry

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].